Redeye comments on Fluoguide’s Q4 2023 report, with the company having recently communicated a strategy update. We believe the company’s new strategy is value-accretive overall, though it likely delays a potential market approval for FG001 by c6-12 months. We do some housekeeping in our model and leave our estimates and valuation largely unchanged.